These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29967227)

  • 21. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
    Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
    Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.
    Pintaudi B; Scatena A; Piscitelli G; Frison V; Corrao S; Manicardi V; Graziano G; Rossi MC; Gallo M; Mannino D; Di Bartolo P; Nicolucci A
    Cardiovasc Diabetol; 2021 Mar; 20(1):59. PubMed ID: 33676499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes: Time for reconciliation between cardiologists and diabetologists.
    Scheen AJ
    Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
    [No Abstract]   [Full Text] [Related]  

  • 25. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Greene SJ; Butler J
    Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
    [No Abstract]   [Full Text] [Related]  

  • 26. Insulin resistance: Impact on therapeutic developments in diabetes.
    Bailey CJ
    Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
    Sarzani R; Giulietti F; Di Pentima C; Spannella F
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
    Tuttle KR; Cherney DZ;
    Clin J Am Soc Nephrol; 2020 Feb; 15(2):285-288. PubMed ID: 31740570
    [No Abstract]   [Full Text] [Related]  

  • 32. SGLT2i: beyond the glucose-lowering effect.
    Ni L; Yuan C; Chen G; Zhang C; Wu X
    Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letter by Potier and Roussel Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes".
    Potier L; Roussel R
    Circulation; 2019 Jan; 139(2):303-304. PubMed ID: 30615503
    [No Abstract]   [Full Text] [Related]  

  • 34. Response by Nassif and Kosiborod to Letter Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes".
    Nassif ME; Kosiborod M
    Circulation; 2019 Jan; 139(2):305-306. PubMed ID: 30615504
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
    Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
    J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
    [No Abstract]   [Full Text] [Related]  

  • 37. Introduction.
    Chilton R
    Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
    [No Abstract]   [Full Text] [Related]  

  • 38. Report from the 5th cardiovascular outcome trial (CVOT) summit.
    Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
    Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
    McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J
    Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Kappel BA; Lehrke M; Schütt K; Artati A; Adamski J; Lebherz C; Marx N
    Circulation; 2017 Sep; 136(10):969-972. PubMed ID: 28874423
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.